Precigen, Inc.
PGENHealthcareNASDAQBiotechnology · Last scanned May 29, 2026
Scan Results
Daily timeframe1 of 4 indicators bullish as of May 28
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune. The $1.61B market capitalization puts PGEN squarely in small-cap range for its industry. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients.
Market Cap
$1.61B
Beta
1.07
P/E (TTM)
—
P/E (Fwd)
-20.50
EPS (TTM)
$-1.21
EPS (Fwd)
$-0.22
ROE
-1145.4%
ROA
-42.1%
Cash
$56.2M
Total Debt
$98.3M
Free CF
-$90.1M
52W Change
241.7%
Annual Financials
Cash vs Debt
The company holds $56.2M in cash, though total debt stands at $98.2M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company is burning cash, with free cash flow at -$90.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -1145.4% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $26.9M (2022) to $9.7M (2025), a 64% decline worth watching.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Precigen, Inc. and its sector.